Company Overview
About LinusBio
LinusBio is a precision medicine and diagnostics company founded by Manish Arora and headquartered in New York, with roots in research at the Icahn School of Medicine at Mount Sinai and MIT. The company has developed a proprietary technology platform called exposome sequencing — a method of analyzing biological samples, primarily hair, to reconstruct a detailed timeline of environmental exposures and biological changes over months or years. This approach enables early detection of disease risk factors by reading both genetic and environmental signals simultaneously.
Business Model & Competitive Advantage
LinusBio's lead clinical focus is early autism spectrum disorder (ASD) detection. Its research has demonstrated that hair samples from children can reveal exposure patterns — including metal dysregulation and nutritional imbalances — that correlate with autism risk beginning in the prenatal period. By identifying these signals earlier than standard behavioral assessments (which typically diagnose ASD at age 3–4), LinusBio aims to enable interventions during critical neurodevelopmental windows. The company has raised $12.5M in a Series A round to advance its diagnostics toward clinical validation and regulatory submission.
Competitive Landscape 2025–2026
Beyond autism, LinusBio's exposome sequencing platform has potential applications across neurodegenerative diseases, metabolic conditions, and environmental health monitoring. The company represents a novel diagnostic paradigm that sits at the intersection of AI analytics, multi-omics biology, and environmental medicine — addressing the longstanding gap in diagnostics that focus almost exclusively on genetic risk while ignoring environmental co-factors.
Key Differentiators
Emerging Innovator
LinusBio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare LinusBio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from LinusBio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim LinusBio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention LinusBio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →